Pionyr Immunotherapeutics Completes $62M Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment

One Bench at a Time

Pionyr Immunotherapeutics Completes $62M Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment

Max Krummel, PhD, Pionyr Co-Founder and Robert E. Smith Endowed Chair in Experimental Pathology, UCSF

Pionyr Immunotherapeutics, a company at QB3@953, is developing antibody therapeutics that increase the body’s antitumor immunity by rebalancing the myeloid infiltrate in the tumor microenvironment, announced the closing of a $62 million Series B investment round. This brings total funding since the company’s founding in 2015 to $72 million. The Series B financing was led by New Enterprise Associates and included Sofinnova Ventures and Vida Ventures, along with Pionyr’s existing investors, OrbiMed, SV Health Investors, Osage University Partners, and Mission Bay Capital.

Research conducted at Pionyr over the past year shows that its most advanced technology, Myeloid Tuning™, is capable of rebalancing the tumor microenvironment to favor immune-activating myeloid cells over immune-suppressing myeloid cells. This activity is believed to enhance antitumor efficacy, particularly in combination with checkpoint inhibition. The proportions of specific subpopulations of myeloid cells in the tumor microenvironment have been shown to correlate with clinical outcome and predict checkpoint inhibitor responsiveness.

Full Press Release

Upcoming Event

  • A Welcome Party for Newcomers! Location: 953 Indiana Street, San Francisco

    15:30-17:00
    08/31/2018
    Please join us for a celebration to welcome all new companies to the MBC BioLabs family! Come and meet the new faces in the building and enjoy some food!

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter